- Investor Relations
- Events & Presentations
- Corporate Governance
- Financial Information
- Stock Information
- Investor FAQs
- Contact Us
| Shareholder Tools: |
Shareholder Briefcase
|
Printed Materials
|
Email Alerts
|
Download Library
|
Glossary
|
RSS News Feeds
|
|
Search Investor Relations: |
STOCK INFORMATION |
|
|---|---|
|
NASDAQ : ACUS
$0.69 - 0.02 |
Jul 3, 2008
1:00 PM ET |
|
Quotes delayed at least 20 minutes. Information provided by TurboFeed. |
|
Board of Directors
hide all-
Frank Baldino, Jr., Ph.D.
-
Frank Baldino, Jr., Ph.D., has served as one of our directors since 2001. Dr. Baldino is the founder of Cephalon, Inc., an integrated specialty biopharmaceutical company involved in the development of therapeutics for neurological disorders, sleep disorders and cancer. He has served as President, Chief Executive Officer and a Director of Cephalon since its inception in 1987 and is currently Chairman of the Board as well. Dr. Baldino holds adjunct academic appointments, including Adjunct Associate Professor of Pharmacology at Temple University School of Medicine, and Adjunct Associate Professor of Physiology and Biophysics and Adjunct Associate Professor of Neurology at Hahnemann University. Dr. Baldino is also a director of Pharmacopeia, Inc., ViroPharma, Incorporated and NicOx S.A.
-
Garen Bohlin
-
Garen Bohlin, has served as one of our directors since 2005. Mr. Bohlin is the Chief Operating Officer for Sirtris Pharmaceuticals, Inc. in Cambridge, M.A. Previous to Sirtris, Mr. Bohlin served as President and CEO of Syntonix Pharmaceuticals, Inc. Prior to joining Syntonix, Mr. Bohlin was Executive Vice President of Genetics Institute where he was responsible for essentially all of the non-scientific areas that comprised approximately half of the then 1600 employees. Mr. Bohlin spent 14 years in executive management at Genetics Institute managing significant growth and playing a leading role in the closing of a broad range of financings. Prior Mr. Bohlin's tenure at Genetics Institute he spent 13 years at Arthur Andersen & Co. In addition to serving on Acusphere's Board, he is also a member of the Board of Directors of Targanta Pharmaceuticals, Inc.
Chair of the Audit Committee
Member of the Nominating and Governance Committee
-
Sandra L. Fenwick
-
Sandra L. Fenwick, has served as one of our directors since 2004. Ms. Fewick is Chief Operating Officer of the world-renowned Children's Hospital in Boston, Massachusetts. Prior to joining Children's Hospital in 1999, Ms. Fenwick was Senior Vice President of System Development for CareGroup, Inc. Before its merger with CareGroup, Ms. Fenwick served at Beth Israel Hospital for 20 years in various areas of increasing responsibility including Vice President and Deputy Director, Vice President of Clinical Services Planning and Development and Vice President of Network Development for Beth Israel Healthcare.
Member of the Audit Committee
Chair of the Compensation Committee
-
Martyn Greenacre
-
Martyn Greenacre, has served as one of our directors since 2001. Mr. Greenacre served in various senior management positions at SmithKline Beecham from 1973 through 1992. From 1989 to 1992, as Chairman Europe, he was responsible for the strategic direction and operational management of pharmaceutical subsidiaries in Europe and for planning and executing European aspects of the merger between SmithKline Beckman and Beecham Pharmaceuticals. He has also served as Chief Executive Officer of two life sciences companies, Zynaxis Inc. from 1993 to 1997 and Delsys Pharmaceutical Corp. from 1997 to 2001. He is also a director of Cephalon, Inc., Curis, Inc. and Immune Response Corp. and a director and chairman of the board of directors of Beijing Med-Pharm Corporation.
Member of the Audit Committee
Chair of the Nominating and Governance Committee
-
Derek Lemke-von Ammon
-
Derek Lemke-von Ammon, has served as a director of the Company since 2002. Mr. Lemke-von Ammon is a General Partner at FTVentures. Previous to joining FTVentures Mr. Lemke-von Ammon was a managing Partner for Thomas Weisel Capital Partners, a Director of Private Equity for Thomas Weisel Partners, and a member of the Firm's Executive Committee until December 2003. Prior to joining Thomas Weisel Capital Partners in 1998, Mr. Lemke-von Ammon was a Senior Managing Director and Director of Private Equity at Montgomery Securities from 1989 to 1998. Prior to joining Montgomery Securities, Mr. Lemke-von Ammon was a Vice President at Dain Bosworth Incorporated where he was employed from 1985 to 1989. He also worked as a corporate and securities attorney from 1983 to 1985 for Bogle & Gates in Seattle.
Member of the Nominating and Governance Committee
Member of the Compensation Committee
-
Sherri C. Oberg
-
Sherri C. Oberg, a co-founder of Acusphere, has served as our President and Chief Executive Officer and one of our directors since our inception in 1993. Prior to joining Acusphere, Ms. Oberg was President and Chief Executive Officer of Neomorphics, Inc., a venture capital backed company focused on tissue engineering, from 1991 to 1992. Prior to joining Neomorphics, she was a venture capitalist at Aegis Venture Funds from 1988 to 1991, and at Inco Venture Capital Management from 1986 to 1988. Ms. Oberg is a member of the Board of Overseers of The Amos Tuck School at Dartmouth College. Ms. Oberg holds a B.A. from Dartmouth College and an M.B.A. from the Amos Tuck School of Business Administration.
© 2002-2008 Acusphere, Inc. :: All Rights Reserved